卡培他滨联合多西他赛治疗蒽环类耐药性乳腺癌的临床研究  

Study on the treatment effect of capecitabine and docetaxel on anthracyclines resistant breast cancer

作　　者：杨君[1] 杨文福[1] Yang Jun Yang Wenfu(Department of Galactophore , the Tumor Hospital of Shanxi Province, Taiyuan , Shanxi 030013, China)

机构地区：[1]山西省肿瘤医院乳腺一科,山西省太原030013

出　　处：《中国基层医药》2017年第1期1-4,共4页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的：研究卡培他滨联合多西他赛对蒽环类耐药性乳腺癌的临床治疗效果，为该病的治疗提供依据。方法回顾性分析2013年1月至2015年1月就诊的100例蒽环类耐药性乳腺癌患者的临床资料，按治疗方法不同分为两组，联合使用卡培他滨与多西他赛治疗（治疗组）患者51例，单纯使用多西他赛治疗（对照组）患者49例。观察两组 KPS 评分、1年生存率、肿瘤进展时间（TTP）以及中位生存期（MST）等指标，并对其治疗有效性与安全性进行比较。结果（1）治疗前，治疗组、对照组 KPS 评分分别为（83．6±1．6）分、（83．4±1．7）分，两组差异无统计学意义（t ＝0．606，P ＞0．05）；治疗后，治疗组、对照组 KPS 评分分别为（89．5±1．2）分、（86．4±1．6）分，治疗组评分明显高于对照组（t ＝10．989，P ＜0．05）。（2）治疗后，治疗组1年生存率、TTP 以及 MST 等指标明显优于对照组[1年生存率：62．74％比40．82％，χ2＝4．815，P ＜0．05；TTP：（8．5±1．1）个月比（6．3±1.2）个月，t ＝9．563，P ＜0．05；MST：（15．6±1．2）个月比（15．6±1．2）个月，t ＝10．871，P ＜0．05]。（3）治疗组有效率、临床获益率均明显高于对照组（有效率：90．19％比63．27％，χ2＝10．234，P ＜0.05；临床获益率：94．12％比73．47％，χ2＝6．466，P ＜0．05）。（4）两组间各种不良反应发生率差异无统计学意义（骨髓抑制：13．73％比12．24％，χ2＝0．048，P ＞0．05；恶心呕吐：11．76％比14．29％，χ2＝0．104，P ＞0.05；便秘：19.61％比18．37％，χ2＝0．025，P ＞0．05；脱发：21．57％比20．41％，χ2＝0．020，P ＞0．05；消化不良：25.49％比22．45％，χ2＝0．127，P ＞0．05；关节疼痛：15．67％比20．41％，χ2＝0．378，P ＞0．05）。结论蒽环类耐药性乳腺癌患者联合使用卡培他滨与多西他赛�Objective To study the treatment effects of capecitabine and docetaxel on anthracyclines resistant breast cancer,so as to provide the evidence for the effective treatment of the disease.Methods 1 00 patients with anthracyclines resistant breast cancer were treated in our hospital from January 201 3 to January 201 5,and they were considered as research subjects in this study.The clinical data were analyzed retrospectively.Capecitabine and docetaxel were used for treatment in the treatment group （n =51 ）,and there were 49 cases treated with docetaxel in the control group.The indexes were observed including KPS score,the rate of survive to 1 year,TTP and MST.The treatment effects and safety were also compared in these two groups.Results （1 ）Before treatment,KPS scores in the treatment group and the control group were （83.6 ±1 .6）points and （83.4 ±1 .7）points respectively,and the difference was not statistically significant （t =0.606,P 〉0.05）.After treatment,the KPS scores were （89.5 ±1 .2）points and （86.4 ±1 .6）points,which of the treatment group was significantly higher than the control group （t =1 0.989,P 〈0.05）.（2）After treatment,1 year survival rate,TTP and MST in the treatment group were significantly higher than those in the control group[1 years survival rate：62.74% vs.40.82%,χ2 =4.815,P 〈0.05;TTP：（8.5 ±1 .1 ）months vs.（6.3 ±1 .2）months,t =9.563,P 〈0.05;MST：（1 5.6 ±1 .2）months vs.（1 5.6 ±1 .2）months,t =1 0.871 ,P 〈0.05].（3）The treatment efficiency and the clinical benefit rate in the treatment group were significantly higher than＆nbsp;those in the control group （the treatment efficiency：90.1 9% vs.63.27%,χ2 =1 0.234,P 〈0.05;clinical benefit rate：94.1 2% vs.73.47%,χ2 =6.466,P 〈0.05）.（4）However,there was no difference about the ratio of adverse reaction between the two groups （bone marrow suppression：1 3.73% vs.1 2.24%,χ2 =0.048,P 〉0.05;nausea and vomiting：1 1 .76% vs.1 4.29%,χ2 =0.1 04,P 〉0.05;const

关 键 词：乳腺肿瘤 卡培他滨 多西他赛 治疗效果 

分 类 号：R737.9[医药卫生—肿瘤]